Table 3.
Summary of adverse events.
| Adverse Event | Varenicline (n=67) | Nicotine Patch (n=73) | Total (N=140) | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Gastrointestinal | 19 | 28.4% | 22 | 30.1% | 41 | 29.3% |
| Vivid Dreams | 18 | 26.9% | 23 | 31.5% | 41 | 29.3% |
| Nausea | 21 | 31.3% | 8 | 11.0% | 29 | 20.7% |
| Insomnia | 13 | 19.4% | 13 | 17.8% | 26 | 18.6% |
| Irritability | 8 | 11.9% | 16 | 21.9% | 24 | 17.1% |
| Headache | 13 | 17.9% | 11 | 15.1% | 23 | 16.4% |
| Respiratory | 7 | 10.4% | 13 | 17.8% | 20 | 14.3% |
| Skin Irritation at Patch Site | 2 | 3.0% | 13 | 17.8% | 15 | 10.7% |
| Drowsiness/Fatigue | 7 | 10.4% | 7 | 9.6% | 14 | 10.0% |
| Anxiety/Depression | 4 | 6.0% | 7 | 9.6% | 11 | 7.9% |
| Dizziness/Lightheadedness | 3 | 4.5% | 8 | 11.0% | 11 | 7.9% |
| Mouth Dryness | 7 | 10.4% | 4 | 5.5% | 11 | 7.9% |
| Musculoskeletal | 5 | 7.5% | 5 | 6.8% | 10 | 7.1% |
| Skin Irritation other than Patch Site | 2 | 3.0% | 7 | 9.6% | 9 | 6.4% |
| Restlessness/Jitteriness | 3 | 4.5% | 5 | 6.8% | 8 | 5.7% |
| Urinary/Genital | 4 | 6.0% | 4 | 5.5% | 8 | 5.7% |
| Increased Heart Rate | 1 | 1.5% | 3 | 4.1% | 4 | 2.9% |
| Fever | 0 | 0% | 1 | 1.4% | 1 | 0.7% |